Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Indian Journal of Gastroenterology
Published in: Indian Journal of Gastroenterology 1/2017

01-01-2017 | Review Article

Management of chronic constipation in patients with diabetes mellitus

Authors: V. G. M. Prasad, Philip Abraham

Published in: Indian Journal of Gastroenterology | Issue 1/2017

Login to get access

Abstract

Aim

The aim of this review is to provide an overview of the clinical assessment and evidence-based treatment options for managing diabetes-associated chronic constipation.

Methods

A literature search of published medical reports in English language was performed using the OVID Portal, from PUBMED and the Cochrane Database of Systematic Reviews, from inception to October 2015. A total of 145 abstracts were identified; duplicate publications were removed and 95 relevant full-text articles were retrieved for potential inclusion.

Results

Chronic constipation is one of the most common gastrointestinal symptoms in patients with diabetes, and occurs more frequently than in healthy individuals. Treatment goals include improving symptoms and restoring bowel function by accelerating colonic transit and facilitating defecation. Based on guidelines and data from published literature, food and dietary change with exercise and lifestyle change should be the first step in management. For patients recalcitrant to these changes, laxatives should be the next step of treatment. Treatment should begin with bulking agents such as psyllium, bran or methylcellulose followed by osmotic laxatives if response is poor. Lactulose, polyethylene glycol and lactitol are the most frequently prescribed osmotic agents. Lactulose has a prebiotic effect and a carry-over effect (continued laxative effect for at least 6 to 7 days, post cessation of treatment). Stimulants such as bisacodyl, sodium picosulphate and senna are indicated if osmotic laxatives are not effective. Newer agents such as chloride-channel activators and 5-HT4 agonist can be considered for severe or resistant cases.

Conclusion

The primary aim of intervention in diabetic patients with chronic constipation is to better manage the diabetes along with management of constipation. The physician should explain the rationale for prescribing laxatives and educate patients about the potential drawbacks of long-term use of laxatives. They should contact their physician if short-term use of prescribed laxative fails to provide relief.
Literature
1.
2.
3.
4.
Forgacs I, Patel V. Diabetes and the gastrointestinal tract. Medicine. 2011;39:288–92.CrossRef
5.
Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care. 2003;26:1553–79.PubMedCrossRef
6.
Phillips LK, Rayner CK, Jones KL, Horowitz M. An update on autonomic neuropathy affecting the gastrointestinal tract. Curr Diab Rep. 2006;6:417–23.PubMedCrossRef
7.
Ueno N, Inui A, Satoh Y. The effect of mosapride citrate on constipation in patients with diabetes. Diabetes Res Clin Pract. 2010;87:27–32.PubMedCrossRef
8.
Cheng C, Chan AO, Hui WM, Lam SK. Coping strategies, illness perception, anxiety and depression of patients with idiopathic constipation: a population-based study. Aliment Pharmacol Ther. 2003;18:319–26.PubMedCrossRef
9.
Maleki D, Locke GR 3rd, Camilleri M, et al. Gastrointestinal tract symptoms among persons with diabetes mellitus in the community. Arch Intern Med. 2000;160:2808–16.
10.
Enck P, Rathmann W, Spiekermann M, et al. Prevalence of gastrointestinal symptoms in diabetic patients and non-diabetic subjects. Z Gastroenterol. 1994;32:637–41.PubMed
11.
Schvarcz E, Palmer M, Ingberg CM, Aman J, Berne C. Increased prevalence of upper gastrointestinal symptoms in long-term type 1 diabetes mellitus. Diabet Med. 1996;13:478–81.PubMedCrossRef
12.
Janatuinen E, Pikkarainen P, Laakso M, Pyorala K. Gastrointestinal symptoms in middle-aged diabetic patients. Scand J Gastroenterol. 1993;28:427–32.PubMedCrossRef
13.
14.
Oh JH, Choi MG, Kang MI, et al. The prevalence of gastrointestinal symptoms in patients with non-insulin dependent diabetes mellitus. Korean J Intern Med. 2009;24:309–17.PubMedPubMedCentralCrossRef
15.
16.
Belsey J, Greenfield S, Candy D, Geraint M. Systematic review: impact of constipation on quality of life in adults and children. Aliment Pharmacol Ther. 2010;31:938–49.PubMed
17.
Lewis SJ, Heaton KW. Stool form scale as a useful guide to intestinal transit time. Scand J Gastoenterol. 1997;32:920–4.CrossRef
18.
Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006;130:1377–90.PubMedCrossRef
19.
Tack J, Muller-Lissner S. Treatment of chronic constipation: current pharmacologic approaches and future directions. Clin Gastroenterol Hepatol. 2009;7:502–8.PubMedCrossRef
20.
Tack J, Muller-Lissner S, Stanghellini V, et al. Diagnosis and treatment of chronic constipation—a European perspective. Neurogastroenterol Motil. 2011;23:697–710.PubMedPubMedCentralCrossRef
21.
22.
23.
Bekele G, Kabadi UM. Gastrointestinal manifestations of diabetes mellitus. Int J Diab Dev Countries. 1996;16:54–8.
24.
Battle WM, Snape WJ, Alavi A, Cohen S, Braunstein S. Colonic dysfunction in diabetes mellitus. Gastroenterology. 1980;79:1217–21.PubMed
25.
Fedorak RN, Field M, Chang EB. Treatment of diabetic diarrhea with clonidine. Ann Intern Med. 1985;102:197–9.PubMedCrossRef
26.
Takahashi T, Matsuda K, Kono T, Pappas TN. Inhibitory effects of hyperglycemia on neural activity of the vagus in rats. Intensive Care Med. 2003;29:309–11.PubMedCrossRef
27.
Horvath VJ, Vittal H, Lorincz A, et al. Reduced stem cell factor links smooth myopathy and loss of interstitial cells of cajal in murine diabetic gastroparesis. Gastroenterology. 2006;130:759–70.PubMedCrossRef
28.
Sanders KM. Interstitial cells of cajal at the clinical and scientific interface. J Physiol. 2006;576 Pt 3:683–7.
29.
Pare P, Ferrazzi S, Thompson WG, Irvine EJ, Rance L. An epidemiological survey of constipation in Canada: definitions, rates, demographics, and predictors of health care seeking. Am J Gastroenterol. 2001;96:3130–7.PubMedCrossRef
30.
American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100 Suppl 1:S1–4.
31.
32.
Rao SS, Welcher KD, Leistikow JS. Obstructive defecation: a failure of rectoanal coordination. Am J Gastroenterol. 1998;93:1042–50.PubMedCrossRef
33.
34.
35.
36.
Ebell MH, Siwek J, Weiss BD, et al. Strength of recommendation taxonomy (SORT): a patient-centered approach to grading evidence in the medical literature. J Am Board Fam Pract. 2004;17:59–67.PubMedCrossRef
37.
Bleser S, Brunton S, Carmichael B, Olden K, Rasch R, Steege J. Management of chronic constipation: recommendations from a consensus panel. J Fam Pract. 2005;54:691–8.PubMed
38.
Jamshed N, Lee ZE, Olden KW. Diagnostic approach to chronic constipation in adults. Am Fam Physician. 2011;84:299–306.PubMed
39.
Gwee KA, Ghoshal UC, Gonlachanvit S, et al. Primary care management of chronic constipation in Asia: the ANMA chronic constipation tool. J Neurogastroenterol Motil. 2013;19:149–60.PubMedPubMedCentralCrossRef
40.
Kay RM. Dietary fiber. J Lipid Res 1982;23:221–42.
41.
Stephen AM, Cummings JH. Mechanism of action of dietary fiber in the human colon. Nature. 1980;284:283–4.
42.
American Diabetes Association. Standards of medical care in diabetes—2016. Diabetes Care. 2016;39:S1–S106.CrossRef
43.
Chen HL, Haack VS, Janecky CW, Vollendorf NW, Marlett JA. Mechanisms by which wheat bran and oat bran increase stool weight in humans. Am J Clin Nutr. 1998;68:711–9.PubMed
44.
Tandon R, Babu S, Chhabra M, et al. Constipation, New Delhi/Gurgaon, Reed Elsevier India Pvt. Ltd, 2013;1–60.
45.
Badiali D, Corazziari E, Habib FI, et al. Effect of wheat bran in treatment of chronic nonorganic constipation. A double-blind controlled trial. Dig Dis Sci. 1995;40:349–56.PubMedCrossRef
46.
Graham DY, Moser SE, Estes MK. The effect of bran on bowel function in constipation. Am J Gastroenterol. 1982;77:599–603.PubMed
47.
Francis CY, Whorwell PJ. Bran and irritable bowel syndrome: time for reappraisal. Lancet. 1994;344:39–40.PubMedCrossRef
48.
Voderholzer WA, Schatke W, Muhldorfer BE, Klauser AG, Birkner B, Muller-Lissner SA. Clinical response to dietary fiber treatment of chronic constipation. Am J Gastroenterol. 1997;92:95–8.PubMed
49.
50.
Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998;280:1490–6.PubMedCrossRef
51.
Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and diabetes study. Diabetes Care. 1997;20:537–44.PubMedCrossRef
52.
Li G, Zhang P, Wang J, et al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet. 2008;371:1783–9.PubMedCrossRef
53.
Knowler WC, Fowler SE, Hamman RF, et al. For diabetes prevention program research group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374:1677–86.PubMedCrossRef
54.
Lindstrom J, Ilanne-Parikka P, Peltonen M, et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet. 2006;368:1673–9.PubMedCrossRef
55.
Tuomilehto J, Lindstrom J, Eriksson JG, et al. For Finnish diabetes prevention study group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343–50.PubMedCrossRef
56.
Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V. For Indian Diabetes Prevention Programme (IDPP). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49:289–97.PubMedCrossRef
57.
Tremaroli V, Bäckhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012;489:242–9.PubMedCrossRef
58.
Larsen N, Vogensen FK, van den Berg FW, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010; 5: e9085.
59.
Cani PD, Neyrinck AM, Fava F, et al. Selective increases of bifidobacteria in gut micrflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007;50:2374–83.PubMedCrossRef
60.
Tuohy KM, Rouzaud GC, Bruck WM, Gibson GR. Modulation of the human gut microflora towards improved health using prebiotics—assessment of efficacy. Curr Pharm Des. 2005;11:75–90.PubMedCrossRef
61.
62.
Tramonte SM, Brand MB, Mulrow CD, Amato MG, O’Keefe ME, Ramirez G. The treatment of chronic constipation in adults. A systematic review. J Gen Intern Med. 1997;12:15–24.PubMedPubMedCentralCrossRef
63.
Odes HS, Madar Z. A double-blind trial of a celandin, aloevera and psyllium laxative preparation in adult patients with constipation. Digestion. 1991;49:65–71.PubMedCrossRef
64.
Coggrave M, Norton C, Cody JD. Management of faecal incontinence and constipation in adults with central neurological diseases. Cochrane Database Syst Rev. 2014; CD002115.
65.
Suares NC, Ford AC. Systematic review: the effects of fibre in the management of chronic idiopathic constipation. Aliment Pharmacol Ther. 2011;33:895–901.PubMedCrossRef
66.
McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998;12:491–7.PubMedCrossRef
67.
Cheskin LJ, Kamal N, Crowell MD, Schuster MM, Whitehead WE. Mechanisms of constipation in older persons and effects of fiber compared with placebo. J Am Geriatr Soc. 1995;43:666–9.PubMedCrossRef
68.
Ashraf W, Park F, Lof J, Quigley EM. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995;9:639–47.PubMedCrossRef
69.
Sierra M, Garcia JJ, Fernandez N, Diez MJ, Calle AP. Therapeutic effects of psyllium in type 2 diabetic patients. Eur J Clin Nutr. 2002;56:830–42.PubMedCrossRef
70.
71.
Lee-Robichaud H, Thomas K, Morgan J, Nelson RL. Lactulose versus polyethylene glycol for chronic constipation. Cochrane Database Syst Rev. 2010; CD007570.
72.
Genovese S, Riccardi G, Rivellese AA. Lactulose improves blood glucose response to an oral glucose test in non-insulin dependent diabetic patients. Diabetes Nutr Metab. 1992;5:295–7.
73.
Cummings JH, Englyst HN. Fermentation in the human large intestine and the available substrates. Am J Clin Nutr. 1987;45:1243–55.PubMed
74.
Bouhnik Y, Neut C, Raskine L, et al. Prospective, randomized parallel-group trial to evaluate the effects of lactulose and polyethylene glycol-4000 on colonic flora in chronic idiopathic constipation. Aliment Pharmacol Ther. 2004;19:889–99.PubMedCrossRef
75.
Ballongue J, Schumann C, Quignon P. Effects of lactulose and lactitol on colonic microflora and enzymatic activity. Scand J Gastroenterol Suppl. 1997;222:41–4.PubMedCrossRef
76.
Sanders JF. Lactulose syrup assessed in a double-blind study of elderly constipated patients. J Am Geriatr Soc. 1978;26:236–9.PubMedCrossRef
77.
Wesselius-De Casparis A, Braadbaart S, Bergh-Bohlken GE, Mimica M. Treatment of chronic constipation with lactulose syrup: results of a double-blind study. Gut. 1968;9:84–6.PubMedPubMedCentralCrossRef
78.
Rouse M, Chapman N, Mahapatra M, Grillage M, Atkinson SN, Prescott P. An open, randomised, parallel group study of lactulose versus ispaghula in the treatment of chronic constipation in adults. Br J Clin Pract. 1991;45:28–30.PubMed
79.
Connolly P, Hughes IW, Ryan G. Comparison of “Duphalac” “and irritant” laxatives during and after treatment of chronic constipation: a preliminary study. Curr Med Res Opin. 1974;2:620–5.PubMedCrossRef
80.
Culbert P, Gillett H, Ferguson A. Highly effective new oral therapy for faecal impaction. Br J Gen Pract. 1998;48:1599–600.PubMedPubMedCentral
81.
Chen CC, Su MY, Tung SY, Chang FY, Wong JM, Geraint M. Evaluation of polyethylene glycol plus electrolytes in the treatment of severe constipation and faecal impaction in adults. Curr Med Res Opin. 2005;21:1595–602.PubMedCrossRef
82.
Dipalma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter, placebo-controlled trial of polyethylene glycol laxative for chronic treatment of chronic constipation. Am J Gastroenterol. 2007;102:1436–41.PubMedCrossRef
83.
Paille FCN, Alleaume B, Vicari F. An open six-month study of the safety of Transipeg for treating constipation in community medicine. J Clin Res. 1992;2:65–76.
84.
Chaussade S, Minić M. Comparison of efficacy and safety of two doses of two different polyethylene glycol-based laxatives in the treatment of constipation. Aliment Pharmacol Ther. 2003;17:165–72.PubMedCrossRef
85.
Dupont C, Leluyer B, Maamri N, et al. Double-blind randomized evaluation of clinical and biological tolerance of polyethylene glycol 4000 versus lactulose in constipated children. J Pediatr Gastroenterol Nutr. 2005;41:625–33.PubMedCrossRef
86.
Di Palma JA, Cleveland MV, McGowan J, Herrera JL. A randomized, multicenter comparison of polyethylene glycol laxative and tegaserod in treatment of patients with chronic constipation. Am J Gastroenterol. 2007;102:1964–71.PubMedCrossRef
87.
Migeon-Duballet I, Chabin M, Gautier A, et al. Long-term efficacy and cost-effectiveness of polyethylene glycol 3350 plus electrolytes in chronic constipation: a retrospective study in a disabled population. Curr Med Res Opin. 2006;22:1227–35.PubMedCrossRef
88.
Corazziari E, Badiali D, Bazzocchi G, et al. Long term efficacy, safety and tolerability of low daily doses of isosmotic polyethylene glycol electrolyte balanced solution (PMF-100) in the treatment of functional chronic constipation. Gut. 2000;46:522–6.PubMedPubMedCentralCrossRef
89.
Loening-Baucke V, Pashankar D. A randomized, prospective, comparison study of polyethylene glycol 3350 without electrolytes and milk of magnesia for children with constipation and fecal incontinence. Pediatrics. 2006;118:528–35.PubMedCrossRef
90.
91.
Freedman MD, Schwartz HJ, Roby R, Fleisher S. Tolerance and efficacy of polyethylene glycol 3350/electrolyte solution versus lactulose in relieving opiate induced constipation: a double-blinded placebo-controlled trial. J Clin Pharmacol. 1997;37:904–7.PubMedCrossRef
92.
Izzo AA, Gaginella TS, Mascolo N, Capasso F. Nitric oxide as a mediator of the laxative action of magnesium sulphate. Br J Pharmacol. 1994;113:228–32.PubMedPubMedCentralCrossRef
93.
Izzo AA, Gaginella TS, Capasso F. The osmotic and intrinsic mechanisms of the pharmacological laxative action of oral high doses of magnesium sulphate. Importance of the release of digestive polypeptides and nitric oxide. Magnes Res. 1996;9:133–8.PubMed
94.
Kinnunen O, Salokannel J. Constipation in elderly long-stay patients: its treatment by magnesium hydroxide and bulk-laxative. Ann Clin Res. 1987;19:321–3.PubMed
95.
96.
Emmanuel A, Cools M, Vandeplassche L, et al. Prucalopride improves bowel function and colonic transit time in patients with chronic constipation: an integrated analysis. Am J Gastroenterol. 2014;109:887–94.PubMedPubMedCentralCrossRef
97.
Emmanuel AV, Roy AJ, Nicholls TJ, Kamm M. Prucalopride, a systemic enterokinetic, for the treatment of constipation. Aliment Pharmacol Ther. 2002;16:1347–56.PubMedCrossRef
98.
Quigley EM, Vandeplassche L, Kerstens R, Ausma J. Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation: a 12-week, randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2009;29:315–28.PubMedCrossRef
99.
Camilleri M, Kerstens R, Rykx A, Vandeplassche L. A placebo-controlled trial of prucalopride for severe chronic constipation. N Engl J Med. 2008;358:2344–54.PubMedCrossRef
100.
Sweetser S, Busciglio IA, Camilleri M, et al. Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor functions in healthy subjects. Am J Physiol Gastrointest Liver Physiol. 2009;296:G295–301.PubMedCrossRef
101.
Johanson JF, Morton D, Geenen J, Ueno R. Multicenter, 4-week, double-blind, randomized, placebo-controlled trial of lubiprostone, a locally-acting type-2 chloride channel activator, in patients with chronic constipation. Am J Gastroenterol. 2008;103:170–7.PubMedCrossRef
102.
Johanson JF, Ueno R. Lubiprostone, a locally acting chloride channel activator, in adult patients with chronic constipation: a double-blind, placebo-controlled, doseranging study to evaluate efficacy and safety. Aliment Pharmacol Ther. 2007;25:1351–61.PubMedCrossRef
103.
Barish CF, Drossman D, Johanson JF, Ueno R. Efficacy and safety of lubiprostone in patients with chronic constipation. Dig Dis Sci. 2010;55:1090–7.PubMedCrossRef
104.
Sucampo receives marketing authorization for Amitiza in Switzerland for treatment of chronic idiopathic constipation, 2009. Sucampo Pharma Europe Ltd. Available via DIALOG. http://​www.​sucampo.​com. Accessed 7 June 2010.
105.
Lembo AJ, Kurtz CB, Macdougall JE, et al. Efficacy of linaclotide for patients with chronic constipation. Gastroenterology. 2010;138:886–95.PubMedCrossRef
106.
Carson RT, Tourkodimitris S, Macdougall JE, et al. Effect of linaclotide on quality of life in adults with chronic constipation: results from two randomized, double-blind, placebo-controlled phase 3 trials. Presented at DDW, May 1–5 2010. Abstract [847d].
107.
Johnston JM, Schneier H, Lavins BJ, et al. Results from the randomized withdrawal period of a phase 3 clinical trial of linaclotide in chronic constipation. Presented at DDW, May 1–5 2010. Abstract [T1817].
108.
McRorie JW, Daggy BP, Morel JG, Diersing PS, Miner PB, Robinson M. Psyllium is superior to docusate sodium for treatment of chronic constipation. Aliment Pharmacol Ther. 1998;12:491–7.PubMedCrossRef
109.
Cheskin LJ, Kamal N, Crowell MD, Schuster MM, Whitehead WE. Mechanisms of constipation in older persons and effects of fiber compared with placebo. J Am Geriatr Soc. 1995;43:666–9.PubMedCrossRef
110.
Ashraf W, Park F, Lof J, Quigley EM. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther. 1995;9:639–47.PubMedCrossRef
111.
Tomas-Ridocci M, Anon R, Minguez M, Zaragoza A, Ballester J, Benages A. The efficacy of Plantago ovata as a regulator of intestinal transit: a doubleblind study compared to placebo. Rev Esp Enferm Dig. 1992;82:17–22.PubMed
112.
Sturtzel B, Elmadfa I. Intervention with dietary fiber to treat constipation and reduce laxative use in residents of nursing homes. Ann Nutr Metab. 2008;52:54–6.PubMedCrossRef
113.
Sturtzel B, Mikulits C, Gisinger C, Elmadfa I. Use of fiber instead of laxative treatment in a geriatric hospital to improve the wellbeing of seniors. J Nutr Health Aging. 2009;13:136–9.PubMedCrossRef
114.
Hamilton JW, Wagner J, Burdick BB, Bass P. Clinical evaluation of methylcellulose as a bulk laxative. Dig Dis Sci. 1988;33:993–8.PubMedCrossRef
115.
Petticrew M, Watt I, Sheldon T. Systematic review of the effectiveness of laxatives in the elderly. Health Technol Assess. 1997;1:1–52.
116.
DiPalma JA, DeRidder PH, Orlando RC, Kolts BE, Cleveland MB. A randomized, placebo-controlled, multicenter study of the safety and efficacy of a new polyethylene glycol laxative. Am J Gastroenterol. 2000;95:446–50.PubMedCrossRef
117.
Cleveland MV, Flavin DP, Ruben RA, Epstein RM, Clark GE. New polyethylene glycol laxative for treatment of constipation in adults: a randomized, double-blind, placebo-controlled study. South Med J. 2001;94:478–81.PubMedCrossRef
118.
Passmore AP, Davies KW, Flanagan PG, Stroker C, Scott MG. A comparison of Agiolax and lactulose in elderly patients with chronic constipation. Pharmacology. 1993;47:249–52.PubMedCrossRef
119.
Passmore AP, Wilson-Davies K, Stoker C, Scott ME. Chronic constipation in long stay elderly patients: a comparison of lactulose and a senna-fiber combination. BMJ. 1993;307:769–71.PubMedPubMedCentralCrossRef
120.
Marlett JA, Li BU, Patrow CJ, Bass P. Comparative laxation of psyllium with and without senna in an ambulatory constipated population. Am J Gastroenterol. 1987;82:333–7.PubMed
121.
Muller-Lissner S, Kamm MA, Musoglu A, Earnest DL, Dunger-Baldauf C, Shetzline MA. Safety, tolerability, and efficacy of tegaserod over 13 months in patients with chronic constipation. Am J Gastroenterol. 2006;101:2558–69.PubMedCrossRef
122.
Towers AL, Burgio KL, Locher JL, Merkel IS, Safaeian M, Wald A. Constipation in the elderly: influence of dietary, psychological, and physiological factors. J Am Geriatr Soc. 1994;42:701–6.PubMedCrossRef
123.
Dukas L, Willett WC, Giovannucci EL. Association between physical activity, fiber intake, and other lifestyle variables and constipation in a study of women. Am J Gastroenterol. 2003;98:1790–6.PubMedCrossRef
124.
Murakami K, Sasaki S, Okubo H, et al. Association between dietary fiber, water and magnesium intake and functional constipation among young Japanese women. Eur J Clin Nutr. 2007;61:616–22.PubMedCrossRef
125.
Okubo H, Sasaki S, Murakami K, et al. Dietary patterns associated with functional constipation among Japanese women aged 18 to 20 years: a cross-sectional study. J Nutr Sci Vitaminol (Tokyo). 2007;53:232–8.CrossRef
126.
Lindeman RD, Romero LJ, Liang HC, Baumgartner RN, Koehler KM, Garry PJ. Do elderly persons need to be encouraged to drink more fluids? J Gerontol A Biol Sci Med Sci. 2000;55:M361–5.PubMedCrossRef
127.
Leung FW. Etiologic factors of chronic constipation: review of the scientific evidence. Dig Dis Sci. 2007;52:313–6.PubMedCrossRef
128.
Brown WJ, Mishra G, Lee C, Bauman A. Leisure time physical activity in Australian women: relationship with well being and symptoms. Res Q Exerc Sport. 2000;71:206–16.PubMedCrossRef
129.
De Schryver AM, Keulemans YC, Peters HP, et al. Effects of regular physical activity on defecation pattern in middle-aged patients complaining of chronic constipation. Scand J Gastroenterol. 2005;40:422–9.PubMedCrossRef
130.
Meshkinpour H, Selod S, Movahedi H, Nami N, James N, Wilson A. Effects of regular exercise in management of chronic idiopathic constipation. Dig Dis Sci. 1998;43:2379–83.PubMedCrossRef
131.
Robson KM, Kiely DK, Lembo T. Development of constipation in nursing home residents. Dis Colon Rectum. 2000;43:940–3.
132.
Anti M, Pignataro G, Armuzzi A, et al. Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation. Hepatogastroenterology. 1998;45:727–32.
Metadata
Title
Management of chronic constipation in patients with diabetes mellitus
Authors
V. G. M. Prasad
Philip Abraham
Publication date
01-01-2017
Publisher
Springer India
Published in
Indian Journal of Gastroenterology / Issue 1/2017
Print ISSN: 0254-8860
Electronic ISSN: 0975-0711
DOI
https://doi.org/10.1007/s12664-016-0724-2

Other articles of this Issue 1/2017

Indian Journal of Gastroenterology 1/2017 Go to the issue

Case Series

Transduodenal ampullectomy for ampullary tumors

Original Article

Role of bedside pancreatic scores and C-reactive protein in predicting pancreatic fluid collections and necrosis

Original Article

Color Doppler—An effective tool for diagnosing midgut volvulus with malrotation

PRESIDENTIAL PROFILE

Dr. T. S. Chandrasekar, incoming president, Indian Society of Gastroenterology 2016–2017

Original Article

Vitamin D status in patients with cirrhosis of the liver and their relatives—A case control study from North India

Original Article

Transjugular liver biopsy in severe alcoholic hepatitis
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits